Abstract:Background: Continuous advancements in medical care have significantly increased the life expectancy of breast cancer (BC) patients. Due to this increased lifespan, combined with genetic, hormonal and environmental factors, BC patients have an increased risk of developing a 2nd primary malignancy. Therefore, regular screening for other types of cancer is of utmost importance for comprehensive care of BC survivors (BCS). The aim of this study was to evaluate the level of compliance with screening for cervical, lung, and colorectal cancer among BCS. Additionally, the study aimed to identify the facilitators and barriers influencing cancer screening (CS) adherence. Methods: An online survey for BCS was developed to assess sociodemographic data, risk perception of developing a 2nd primary malignancy, attitudes towards CS, and compliance with CS. It was distributed through the social media of Mexican oncology-related NGOs. Results: In total, 52 BCS (median age: 44 years, range: 28-67 years) answered the survey. Most were diagnosed with stage III (38%) or II (29%) BC. The majority had completed at least high-school education (90%), had public health insurance (60%) or no insurance (25%), and reported a monthly income < 500 USD (52%). A total of 3 (6%) cases of 2nd primary malignancies were reported, including 2 cases of contralateral BC and 1 cervical carcinoma. Among 50 participants with an indication for cervical CS, 37 (74%) had a pap smear within the past 3 years. Only 7/24 (29%) eligible participants underwent colorectal CS within the last 10 years. Screening modalities included 6 colonoscopies and 1 occult blood test. The primary reason for non-compliance in both cervical and colorectal CS was the absence of a physician's recommendation, accounting for 79% and 88% of the cases, respectively. None of the participants had an indication for lung CS, thus no low-dose computed tomographies were performed for this purpose. Participants demonstrated a mean knowledge score of 72/100 (SD=19) regarding CS. Most respondents mentioned that, compared to the general population, they considered themselves to be at no/very low/low risk of developing cervical (75%), colon (73%), or lung cancer (75%). In terms of attitudes towards CS, an overwhelming majority of participants (98%) affirmed that BCS should undergo screening for other types of cancer. Most stated that, if recommended by a physician, they would agree/strongly agree (96%) to undergo screening for other neoplasms. Nearly all agreed/strongly agreed (98%) that being screened for other types of cancer would be beneficial for their own health; and agreed/strongly agreed (98%) that CS is the most effective way to approach other types of cancer. Additionally, most agreed/strongly agreed (96%) their CS would benefit their family members. On univariate analysis, no sociodemographic or clinical factors were associated with CS adherence. However, it is important to note that the study may have been underpowered to detect significant associations due to the limited sample size. Conclusion: In conclusion, even though most BCS acknowledge its importance, screening for 2nd primary malignancies in this group exhibits suboptimal rates. This study highlights the potential role that BC oncologists could play on increasing CS uptake by reminding patients of their corresponding recommendations to detect other types of cancer. Further research is crucial to enhance our understanding of the key factors influencing these outcomes and to contribute to the development of targeted strategies aimed at enhancing CS adherence. Citation Format: Fernanda Mesa-Chavez, Misael Salazar-Alejo, Cynthia Villarreal-Garza. Screening adherence for second primary malignancies in breast cancer survivors: a cross-sectional study assessing behaviors, facilitators, and barriers to enhance quality care [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO4-12-02.

Primary care provider attitudes about and tendency to use non-recommended surveillance tests after curative breast cancer treatment

Post-polypectomy Guideline Adherence: Importance of Belief in Guidelines, Not Guideline Knowledge or Fear of Missed Cancer

Inadequate Systems to Support Breast and Cervical Cancer Screening in Primary Care Practice

The utility of surveillance CT scans in a cohort of survivors of colorectal cancer

The Role of Primary Care Providers in Lung Cancer Screening: A Cross-Sectional Survey

Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry

Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer

Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30)

Patterns and Predictors of Referral for Screening Breast MRI: A Mixed-Methods Study

Sociodemographic and Clinical Characteristics Associated with Genetic Testing among Cancer Survivors: Evidence from Three Cancer Registries

Physician Perception of Grade Group 1 Prostate Cancer

Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer

Breast Cancer Risk Assessment and Primary Prevention Advice in Primary Care: A Systematic Review of Provider Attitudes and Routine Behaviours

Compliance and satisfaction with BRCA surveillance in specialized clinics versus community follow-up

A National Survey of Pulmonologists' Views on Low-Dose Computed Tomography Screening for Lung Cancer

Abstract PO4-12-02: Screening adherence for second primary malignancies in breast cancer survivors: a cross-sectional study assessing behaviors, facilitators, and barriers to enhance quality care

Real-world genomic testing patterns in patients with prostate cancer.

Opinions and Practices of Lung Cancer Screening by Physician Specialty

Surveillance for Peritoneal Carcinomatosis

Adherence to post-polypectomy surveillance guidelines: a systematic review and meta-analysis

Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer